Visualitza per autor "Morgensztern, Daniel"
Ara mostrant els elements 1-2 d 2
-
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
Felip Font, Enriqueta; Morgensztern, Daniel; Trigo, José Manuel; Moreno, Victor; Curigliano, Giuseppe; Rutkowski, Piotr (Springer, 2022-04) -
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas
Wermke, Martin; Felip Font, Enriqueta; Gambardella, Valentina; Kuboki, Yasutoshi; Morgensztern, Daniel; Hamed, Zohra Oum’ (Future Medicine, 2022-08)